Table 1 Comparison of baseline characteristics
| FOLFOX4 (EACH) | Sorafenib (ORIENTAL) | |||
|---|---|---|---|---|
| n | % | n | % | |
| N | 184 | 150 | ||
| Age | 49.53 (mean) | 51 (median) | ||
| Male | 166 | 90.2 | 127 | 81.7 |
| HBV infection | 171 | 92.9 | 106 | 70.7 |
| HCV infection | 9 | 4.9 | 16 | 10.7 |
| Child–Pugh stage | ||||
| A | 163 | 88.6 | 146 | 97.3 |
| B | 21 | 11.4 | 4 | 2.7 |
| BCLC stage | ||||
| B | 39 | 21.2 | ||
| C | 145 | 78.8 | 143 | 95.3 |
| Extrahepatic spread | 104 | 56.5 | 103 | 68.7 |